Clinical and immunologic features of 56 CD10- pre-B ALL
Characteristics . | CD10– pre-B ALL MLL– . | CD10– pre-B ALL MLL+ . | Total . | P . |
|---|---|---|---|---|
| No. | 10 | 46 | 56 | |
| Sex | ||||
| Male | 1 | 15 | 16 | NS |
| Female | 9 | 32 | 41 | NS |
| Median age, y, (range) | 42.5 (18-78) | 39.5 (15-71) | 40 (15-78) | NS |
| WBC count, × 106/L* | ||||
| Less than 30 000 | 8 | 9 | 17 | NS |
| Greater than 30 000 | 1 | 36 | 37 | <.001 |
| Range | 1600-43 600 | 2600-735 000 | 1600-735 000 | – |
| Median | 9200 | 70 150 | 50 000 | .001 |
| Immunophenotype, n/total | ||||
| CD34 | 8/10 | 18/46 | 26/56 | .02 |
| TdT | 10/10 | 40/46 | 50/56 | NS |
| CD33 greater than 20%† | 2/10 | 3/45 | 5/55 | NS |
| CD65 greater than 20%* | 2/9 | 30/45 | 32/54 | .01 |
| NG2 greater than 20%‡ | 1/2 | 18/18 | 19/20 | .002 |
Characteristics . | CD10– pre-B ALL MLL– . | CD10– pre-B ALL MLL+ . | Total . | P . |
|---|---|---|---|---|
| No. | 10 | 46 | 56 | |
| Sex | ||||
| Male | 1 | 15 | 16 | NS |
| Female | 9 | 32 | 41 | NS |
| Median age, y, (range) | 42.5 (18-78) | 39.5 (15-71) | 40 (15-78) | NS |
| WBC count, × 106/L* | ||||
| Less than 30 000 | 8 | 9 | 17 | NS |
| Greater than 30 000 | 1 | 36 | 37 | <.001 |
| Range | 1600-43 600 | 2600-735 000 | 1600-735 000 | – |
| Median | 9200 | 70 150 | 50 000 | .001 |
| Immunophenotype, n/total | ||||
| CD34 | 8/10 | 18/46 | 26/56 | .02 |
| TdT | 10/10 | 40/46 | 50/56 | NS |
| CD33 greater than 20%† | 2/10 | 3/45 | 5/55 | NS |
| CD65 greater than 20%* | 2/9 | 30/45 | 32/54 | .01 |
| NG2 greater than 20%‡ | 1/2 | 18/18 | 19/20 | .002 |
Each column gives the number of patients with a specific feature. The χ2 test was used to compare the clinical parameters of MLL rearrangement-positive and -negative patients. Median values were compared by the 2-sided Wilcoxon Mann-Whitney test.
NS indicates not significant; WBC, white blood cell; and –, not done.
Data missing for 2 patients
Data missing for 1 patient
Data missing for 36 patients